| abstract |
The present invention relates to improved compositions and methods for treating diseases, such as cancers expressing aberrantly glycosylated MUCl protein, by providing cellular immunotherapy wherein the cellular immunotherapy is a receptor expressing a chimeric antigen that binds to aberrantly glycosylated MUCl protein. immunoregulatory cells of the body (CAR). The invention further relates to polynucleotides, expression vectors and immunoregulatory cells comprising immunotherapy, and related methods. |